PDF下载 ( 428 KB)
Clinical practice guidelines for the interventional treatment of advanced pancreatic carcinoma( on trial)
-
摘要:
<正>1晚期胰腺癌的定义本指南所指晚期胰腺癌(advanced pancreatic carcinoma,APC)为胰腺导管细胞癌,已发生局部和(或)远处转移,无法进行外科手术切除[1],TNM分期在T3N0M0以上,具体分期见表1。
-
Key words:
- pancreatic neoplasms /
- interventional treatment /
- practice guideline
-
[1]EDGE SB,FRITZ AG,BYRD DR,et al.Purpose and principles of cancer staging and staging forms.cancer staging manual(chapter1)[M].7th ed.American Joint Committee on Cancer,2010. [2]SOBIN LH,GOSPODAROWICZ MK,WITTEKIND C,et al.TNMclassification of malignant tumours[M].7th ed.Chichester,West Sussex,UK;Hoboken,NJ:Wiley-Blackwell,2010. [3]CHEN W,ZHENG R,BAADE PD,et al.Cancer Statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132. [4]FURUKAWA H,OKADA S,SAISHO H,et al.Clinicopathologic features of small pancreatic adenocarcinoma.A collective study[J].Cancer,1996,78(5):986-990. [5]HIDAGOM M.Pancreatic cancer[J].N Engl J Med,2010,362(17):1605-1617. [6]BRUGGE WR.Endoscopic ultrasonography:the current status[J].Gastroenterology,1998,115(6):1577-1583. [7]Group of Pancreas Surgery,Chinese Society of Surgery,Chinese Medical Association.Guidelines for the management of pancreatic cancer(2014)[J].J Clin Hepatol,2014,30(12):1240-1245.(in Chinese)中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南(2014)[J].临床肝胆病杂志,2014,30(12):1240-1245. [8] Group of Pancreas Surgery,Chinese Society of Surgery,Chinese Medical Association.Expert consensus on prevention and treatment of common surgical complications after pancreatic operation(2010)[J].Chin J Surg,2010,48(18):1365-1368.(in Chinese)中华医学会外科学分会胰腺外科学组.胰腺术后外科常见并发症预防及治疗的专家共识(2010)[J].中华外科杂志,2010,48(18):1365-1368. [9]NI QX,YU XR,LIU L.Discussion for the clinical definition of pancreatic cancer in China[J].China Oncol,2012,22(2):81-87.(in Chinese)倪泉兴,虞先濬,刘亮.中国胰腺癌临床诊断标准的探讨[J].中国癌症杂志,2012,22(2):81-87. [10]SHI HB,YANG MJ,WANG XL,et al.Feeding arteries of advanced pancreatic cancer:evaluation of 218 patients by digital subtract angiography[J].Clin Med J China,2014,21(1):61-62.(in Chinese)施惠斌,杨敏捷,王小林,等.晚期胰腺癌患者的肿瘤血供来源:218例患者的DSA评价[J].中国临床医学,2014,21(1):61-62. [11]SCHACHTER P,AVNI Y,GVIRZ G.The impact of laparoscopy and laparoscopic ultrasound on the management of pancreatic cystic lesions[J].Arch Surg,2000,135(3):260-264. [12]HESS V,GLIMEUS B,GRAWE P,et al.CA 19-9 tumourmarker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial[J].Lancet Oncol,2008,9(2):132-138. [13]MAITHELS K,MALONEY S,WINSTON C,et al.Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma[J].Ann Surg Oncol,2008,15(12):3512-3520. [14]TAKAHASHI H,OHIASHI H,ISHIKAWA O,et al.Serum CA19-9 alterations during preoperative gemcitabinebased chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival[J].Ann Surg,2010,251(3):461-469. [15]GOONNETILLEKE KS,SIRWARDENA AK.Systematic review of carbohydrate antigen(CA 19-9)as a biochemical marker in the diagnosis of pancreatic cancer[J].Eur J Surg Oncol,2007,33(3):266-270. [16]TEMPERO MA,MALAFA MP,M AL-HAWARY,et al.NCCNGuidelines Version 2.2016 Pancreatic Adenocarcinoma Version 2[C].2016,08/16/16National Comprehensive Cancer Network,Inc.2016. [17]NIMURA Y,NAGINO M,TAKAO S,et al.Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas.Long-term results of a Japanese multicenter randomized controlled trial[J].J Hepatobiliary Pancreat Sci,2012,19(3):230-241. [18]JANG JY,KANG MJ,HEO JS,et al.A prospective randomized controlled study comparing outcomes of standard resection and extended resection,including dissection of the nerve plexus and various lymph nodes,in patients with pancreatic head cancer[J].Ann Surg,2014,259(4):656-664. [19]SIEGEL R,MA J,ZOU Z,et al.Cancer statistics,2014[J].CACancer J Clin,2014,64(1):9-29. [20]National Cancer Network.Clinical practice guidelines in oncology.pancreatic adenocarcinoma.version 2[EB/OL].(2014)[2015-02-01].http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [21]TOL JA,GOUMA DJ,BASSI C,et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma:A consensus statement by the International Study Group on Pancreatic Surgery(ISGPS)[J].Surgery,2014,156(3):591-600. [22]BOCKHORN M,UZUNOGLU FG,ADHAM M,et al.Borderline resectable pancreatic cancer:a consensus statement by the International Study Group of Pancreatic Surgery(ISGPS)[J].Surgery,2014,155(6):977-988. [23]HARTWIG W,VOLLMER CM,FINGERHUT A,et al.Extended pancreatectomy in pancreatic ductal adenocarcinoma:definition and consensus of the International Study Group for Pancreatic Surgery(ISGPS)[J].Surgery,2014,156(1):1-14. [24]ASBUN HJ,CONLON K,FERNANDEZ-CRUZ L,et al.When to performa pancreatoduodenectomy in the absence of positive histology?Aconsensus statement by the International Study Group of Pancreatic Surgery[J].Surgery,2014,155(5):887-892. [25]Interventional Organization,Radiology Branch,Chinese Medical Association,China.Guide to intra-arterial infusion chemotherapy for pancreatic cancers(draft text)[J].J Intervent Radiol,2012,21(5):353-355.(in Chinese)中华医学会放射学分会介入学组.胰腺癌经动脉灌注化疗指南(草案)[J].介入放射学杂志,2012,21(5):353-355. [26]Japan Pancreas Society.Classification of pancreatic carcinoma[M].2nd English ed.Tokyo:Kanehara&Co,Ltd,2003. [27]PHILIP PA,BENEDETTI J,CORLESS CL,et al.PhaseⅢstudy comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest Oncology Group directed intergroup trial S0205[J].J Clin Oncol,2010,28(22):3605-3610. [28]KINDLER HL,NIEDZWIECKI D,HOLLIS D,et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phaseⅢtrial of the Cancer and Leukemia Group B(CALGB 80303)[J].J Clin Oncol,2010,28(22):3617-3622. [29] MOORE MJ,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966. [30]TANAKA T,SAKAGUCHI H,SHO M,et al.A novel interventional radiology technique for arterial infusion chemotherapy against advanced pancreatic Cancer[J].AJR Am J Roentgenol,2009,192(2):168-177. [31]CONROY T,DESSEIGNE F,YCHOU M,et al.FOLFIRINOXversus gemcitabine for metastatic pancreatic cancer[J].N Engl JMed,2011,364(19):1817-1825. [32]KULKE MH,TEMPERO MA,NIEDZWIECKI D,et al.Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin,docetaxel,or irinotecan in patients with metastatic pancreatic cancer:CALGB 89904[J].J Clin Oncol,2009,27(3):5506-5512. [33]CUNNINGHAM D,CHAU I,STOCKEN DD,et al.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J].J Clin Oncol,2009,27(33):5513-5518. [34]LOUVET C,LABIANCA R,HAMMEL P,et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GER-COR and GISCAD phase III trial[J].J Clin Oncol,2005,23(15):3509-3516. [35]OETTLE H,RICHARDS D,RAMANATHAN RK,et al.A phase IIItrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J].Ann Oncol,2005,16(10):1639-1645. [36]ABOU-ALFA GK,LETOURNEAU R,HARKER G,et al.Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer[J].J Clin Oncol,2006,24(27):4441-4447. [37]TEMPERO M,PLUNKETT W,RUIZ van HAPEREN V,et al.Randomized phase II comparison of dose-intense gemcitabine:thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma[J].J Clin Oncol,2003,21(18):3402-3408. [38]MENON KV,GOMEZ D,SMITH AM,et al.Impact of margin status on survival following pancreatoduo-denectomy for cancer:the Leeds Pathology Protocol(LEEPP)[J].HPB(Oxford),2009,11(1):18-24. [39]XU YC,ZHAO TJ,QIAN ZF,et al.CT-guided percutaneous implantation of125I seed for carcinoma of head of pancreas[J].Chin JMin Inv Surg,2013,13(10):865-868.(in Chinese)徐元昌,赵铁军,乔占峰,等.CT引导经皮穿刺125I粒子植入治疗胰头癌[J].中国微创外科杂志,2013,13(10):865-868. [40]LU J,WANG ZM,CHEN KM.CT-guided radioactive125I-seed implantation for the treatment of pancreatic carcinoma:a clinical observation of 19 cases[J].J Intervent Radiol,2010,19(7):550-553.(in Chinese)陆健,王忠敏,陈克敏.CT导引下植入125I粒子治疗19例晚期胰腺癌的疗效观察[J].介入放射学杂志,2010,19(7):550-553. [41]LUNDIN J,ROBERTS PJ,KUUSELA P,et al.Prognostic significance of serum CA242 in pancreatic cancer.A comparison with CA19-9[J].Anticancer Res,1995,15(5B):2181-2186. [42]BALZANO G,di CARLO V.Is CA 19-9 useful in the management of pancreatic cancer?[J].Lancet Oncol,2008,9(2):89-91. [43]LIU LX,WANG JH,WANG XL,et al.Treatment of advanced pancreatic cancer by transarterial infusion of gemcitabine[J].Chin Comput Med Imag,2007,13(3):202-207.(in Chinese)刘凌晓,王建华,王小林,等.中晚期胰腺癌动脉灌注吉西他滨化疗的疗效分析[J].中国医学计算机成像杂志,2007,13(3):202-207. [44]SHI HF,JIN ZY,ZHOU ZQ,et al.Transarterial infusion chemotherapy with a combination of gemcitabine and 5-fluorouracil in advanced pancreatic carcinoma[J].Chin J Radiol,2002,36(12):1072-1074.(in Chinese)石海峰,金征宇,周智强,等.经动脉灌注盐酸吉西他滨和5-氟尿嘧啶治疗中晚期胰腺癌的疗效分析[J].中华放射学杂志,2002,36(12):1072-1074. [45]HUANG J,TIAN DH,ZHANG J,et al.Therapeutic effects of gemcitabine regional artery perfusion combined with systemic chemotherapy for late-stage cancer of pancreas[J].Chin J Gen Surg,2007,16(5):471-473.(in Chinese)黄洁,田大广,张捷,等.吉西他滨区域性动脉灌注联合全身化疗治疗晚期胰腺癌[J].中国普通外科杂志,2007,16(5):471-473. [46]LIU LX,WANG JH,WANG XL,et al.A retrospective analysis of patients with unresectable pancreatic cancer treated with combined transarterial intervention and three dimensional conformal radiotherapy[J].China Oncol,2011,21(1):46-51.(in Chinese)刘凌晓,王建华,王小林,等.介入治疗联合三维适形放疗治疗不能手术切除的胰腺癌患者疗效分析[J].中国癌症杂志,2011,21(1):46-51. [47]VINCENT A,HERMAN J,SCHULICK R,et al.Pancreatic cancer[J].Lancet,2011,378(9791):607-620. [48]LI D,XIE K,WOLFFR R,et al.Pancreatic cancer[J].Lancet,2004,363(9414):1049-1057. [49]BERGER AC,GARCIA M Jr,HOFFMAN JP,et al.Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation:a prospective validation by RTOG 9704[J].J Clin Oncol,2008,26(36):5918-5922. -
本文二维码
计量
- 文章访问数: 282
- HTML全文浏览量: 13
- PDF下载量: 471
- 被引次数: 0
下载:
